madman
Super Moderator
LONG-TERM TESTOSTERONE THERAPY IMPROVES RENAL FUNCTION IN MEN WITH FUNCTIONAL HYPOGONADISM: EXPERIENCE FROM AN OBSERVATIONAL REGISTRY STUDY (2022)
Karim Sultan Haider, Ahmad Haider, Gheorghe Doros, Farid Saad, Abdulmaged Traish Private Urology Practice, Bremerhaven, Germany; Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA; Consultant, Bayer AG, Berlin, Germany; Research Department, Gulf Medical University, Ajman, UAE; Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, MA, USA
Introduction: Reduced estimated glomerular filtration rate (eGFR) is associated with an increased risk of cardiovascular disease and mortality.
Methods: In a registry of 796 men with symptomatic functional hypogonadism, 394 men (49.5%) received testosterone therapy (TTh) by testosterone undecanoate (TU) injections of 1000mg/12weeks following an initial 6-week interval (T-group). 402 men opted against TTh and served as controls (CTRL). 13-year data are presented. Means and standard deviations of absolute measures over 13 years are reported. eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae.
Results: Mean age at baseline: 60.9±6.0 years (T-group: 58.5±6.3, CTRL: 63.2±4.8). Mean (median) follow-up: T-group 10.1±3.0(11), CTRL 10.5±3.0(12) years. Creatinine (mg/dL) decreased from 0.92±0.14 to 0.80±0.06 in the T-group and increased from 1.00±0.14 to 1.25±0.37 in CTRL (p<0.0001 for both). Systolic blood pressure (mmHg) decreased in the T-group from 155.8±16.4 to 129.5±5.9 and increased in CTRL from 142.2±13.9 to 157.2±12.2 (p<0.0001 for both). Diastolic blood pressure decreased in the T-group from 92.9±11.7 to 75.0±3.5 and increased in CTRL from 81.6±8.9 to 93.6±7.0 (p<0.0001 for both). T-group: eGFR (MDRD) (mL/min/1.73 m²) increased from 85.9±11.8 to 95.6±7.7. CTRL: eGFR decreased from 77.4±12.0 to 59.1±10.9) (p<0.0001 for both). T-group: eGFR (CKD-EPI) (mL/min/1.73 m²) increased from 88.6±14.0 to 89.5±4.4 (p<0.05). CTRL: eGFR decreased from 77.3±13.8 to 52.5±12.6) (p<0.0001). 37 deaths (9.4%), 1 myocardial infarction (MI) and no stroke occurred in the T-group. In CTRL, 111 deaths (27.6%), 86 MIs (21.4%) and 73 strokes (18.2%) were recorded (p<0.0001 for all). Adherence to testosterone was 100% as injections were administered in the office and documented.
Conclusion: Long-term testosterone therapy in men with hypogonadism and T2DM prevents age-related deterioration in GFR.
Karim Sultan Haider, Ahmad Haider, Gheorghe Doros, Farid Saad, Abdulmaged Traish Private Urology Practice, Bremerhaven, Germany; Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA; Consultant, Bayer AG, Berlin, Germany; Research Department, Gulf Medical University, Ajman, UAE; Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, MA, USA
Introduction: Reduced estimated glomerular filtration rate (eGFR) is associated with an increased risk of cardiovascular disease and mortality.
Methods: In a registry of 796 men with symptomatic functional hypogonadism, 394 men (49.5%) received testosterone therapy (TTh) by testosterone undecanoate (TU) injections of 1000mg/12weeks following an initial 6-week interval (T-group). 402 men opted against TTh and served as controls (CTRL). 13-year data are presented. Means and standard deviations of absolute measures over 13 years are reported. eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae.
Results: Mean age at baseline: 60.9±6.0 years (T-group: 58.5±6.3, CTRL: 63.2±4.8). Mean (median) follow-up: T-group 10.1±3.0(11), CTRL 10.5±3.0(12) years. Creatinine (mg/dL) decreased from 0.92±0.14 to 0.80±0.06 in the T-group and increased from 1.00±0.14 to 1.25±0.37 in CTRL (p<0.0001 for both). Systolic blood pressure (mmHg) decreased in the T-group from 155.8±16.4 to 129.5±5.9 and increased in CTRL from 142.2±13.9 to 157.2±12.2 (p<0.0001 for both). Diastolic blood pressure decreased in the T-group from 92.9±11.7 to 75.0±3.5 and increased in CTRL from 81.6±8.9 to 93.6±7.0 (p<0.0001 for both). T-group: eGFR (MDRD) (mL/min/1.73 m²) increased from 85.9±11.8 to 95.6±7.7. CTRL: eGFR decreased from 77.4±12.0 to 59.1±10.9) (p<0.0001 for both). T-group: eGFR (CKD-EPI) (mL/min/1.73 m²) increased from 88.6±14.0 to 89.5±4.4 (p<0.05). CTRL: eGFR decreased from 77.3±13.8 to 52.5±12.6) (p<0.0001). 37 deaths (9.4%), 1 myocardial infarction (MI) and no stroke occurred in the T-group. In CTRL, 111 deaths (27.6%), 86 MIs (21.4%) and 73 strokes (18.2%) were recorded (p<0.0001 for all). Adherence to testosterone was 100% as injections were administered in the office and documented.
Conclusion: Long-term testosterone therapy in men with hypogonadism and T2DM prevents age-related deterioration in GFR.
